Senses Disorder TRIZ Cases

Amino acid alterations in the Fc region decrease activating receptor binding while maintaining inhibitory receptor interaction.

Modified indole derivatives selectively inhibit splicing regulatory sequences, reducing cellular toxicity and eliminating DNA intercalation risks.

Horizontal microdroplet delivery via a piezoelectric ejector reduces drug wastage and blinking reflex discomfort.

Banaba and guava leaf extracts inhibit photooxidation of A2E caused by blue light, preventing retinal pigment epithelial cell death.

Antisense oligonucleotides target natural antisense transcripts to resolve specificity and delivery trade-offs in gene modulation.

Selective inhibition of p38 MAPK gamma and delta isoforms reduces systemic toxicity while maintaining anti-inflammatory efficacy for chronic lung diseases.

Micronised hypoglycaemic sulfonamide suspension with thickeners resolves tablet crushing inaccuracies.

Site-specific cysteine engineering creates uniform antibody-drug conjugates, resolving heterogeneity and stability issues from random lysine attachment.

Chiral oxamide intermediate enables amidation reaction maintaining high enantiomeric excess, reducing yield loss in dorzolamide hydrochloride production.

Administering 9-cis-retinyl esters regenerates rhodopsin to stabilize photoreceptor function in aging eyes.

Modified antisense oligonucleotides regulate BDNF mRNA levels through specific hybridization and enzymatic degradation.

Anti-human IL-21 monoclonal antibodies bind specific epitopes to modulate immune responses in autoimmune disorders.

Divided doses of the oxadiazole compound modulate premature translation termination while reducing cumulative adverse effects.

Segmented EF-1α introns enhance protein production while fitting large genes into constrained AAV vectors.

Nitrogenous heterocyclic peptide derivatives containing hydroxymethyl groups and double-substituted beta-alanine chains provide carbonyl-quenching activity.

Dihydro-benzo-oxazine compounds selectively inhibit the PI3Kδ enzyme to reduce immunopathology in parasitic infections.

Mutated FGF-1 polypeptides restore tear film stability to resolve inconsistent dry eye treatment effectiveness.

Structural variants of Formula I compounds modulate VAP-1 enzymatic functions to address inadequate treatment options for uveitis.

Extended maintenance intervals following a loading phase reduce injection burden while maintaining anatomical responses in proliferative diabetic retinopathy.

An IP receptor antagonist blocks prostanoid receptors to decrease VEGF secretion, reducing laser-induced choroidal neovascularization area.

Formula I compounds inhibit IDO protease while resisting metabolic degradation, reducing toxicity in tumor treatment.

Bryostatin and retinoid nanospheres deliver synergistic therapy via oral administration.

Polyarginine peptides block excitotoxic neuronal death to prevent secondary damage from stroke or traumatic brain injury.

Selective hydroxybenzamide derivatives target hyperactive Hsp90 in tumor cells, degrading client proteins while sparing normal tissue.

Novel KCNK13 antagonist compounds selectively inhibit ion channels to reduce inflammatory responses.

Modular substitution patterns on the pyrazino[1,2-a]indole core optimize sigma receptor selectivity and drugability.

Hypercompressed microparticles release ophthalmic drugs via diffusion, solving poor absorption and frequent dosing challenges.

Polyvinylpyrrolidone improves solubility of JAK kinase inhibitors, resolving stability and efficacy trade-offs in dry eye treatments.

PRG4 protein deposits a protective coating on endothelial surfaces to block cell motility, reducing metastasis and thrombosis risks.

Benzocycloheptanethiophene derivatives reduce sedation by modifying lipophilicity parameters while maintaining anti-allergic efficacy.

Anticholinergic zwitterions slow myopia progression by reducing systemic side effects associated with traditional agents.

Selective S1P receptor modulators reduce side effects by targeting specific receptor subtypes.

Core-shell nanoparticles formed from electrostatically interacting polysaccharides stabilize therapeutic proteins and enable controlled release profiles.

A composition of vitamins A, C, E, magnesium, and optional withanolide or resveratrol targets the inner ear to reduce oxidative stress and improve blood flow.

Deuterium substitution at the 17-position blocks CYP2D6-mediated O-demethylation, reducing dextrorphan formation and adverse side effects.

Modular azole amide scaffolds optimize binding affinity to resolve the trade-off between therapeutic efficacy and molecular complexity.

Permeation enhancers in hydrogels boost antibiotic flux across the tympanic membrane, resolving low middle ear concentrations from systemic therapy.

Placenta-derived adherent stromal cells resolve immune rejection during tissue regeneration by utilizing low-immunogenicity biological material.

Aminopyridine compounds inhibit protein farnesylation, rescuing nuclear shape abnormalities and premature differentiation without cellular toxicity.

Substituted triazoles inhibit Axl kinase to treat solid tumors and angiogenesis.

Compounds inhibit 11beta-HSD1 to reduce hepatic glucose output and improve insulin sensitivity without disrupting plasma cortisol homeostasis.

An adenosine derivative acts as a selective A3 receptor antagonist to lower intraocular pressure.

A multivalent pneumococcal vaccine formulation incorporating serotype 22F capsular saccharide conjugates to enhance infant immunogenicity.

Cyclodextrin-complexed pazopanib salts prevent precipitation and eliminate repeated injections.

Segmented spray granulation achieves content uniformity and tensile strength despite large drug-to-drug ratios.